Tranylcypromine‐Based LSD1 Inhibitors: Structure‐Activity Relationships, Antiproliferative Effects in Leukemia, and Gene Target Modulation
暂无分享,去创建一个
A. Mai | S. Minucci | C. Mercurio | A. Mattevi | M. Varasi | D. Rotili | S. Valente | Anna Cappa | S. Vultaggio | C. Zwergel | P. Vianello | O. A. Botrugno | R. Fioravanti | Davide Corinti | Nicola Mautone | Annarita Rovere | P. Dessanti | C. Binda | Annalisa Romanelli | Elisabetta Di Bello
[1] A. Melnick,et al. ORY-1001, a Potent and Selective Covalent KDM1A Inhibitor, for the Treatment of Acute Leukemia. , 2018, Cancer cell.
[2] Sophie A. L. Rousseaux,et al. Electrophilic Zinc Homoenolates: Synthesis of Cyclopropylamines from Cyclopropanols and Amines. , 2017, Journal of the American Chemical Society.
[3] P. Atadja,et al. Upregulation of CD11b and CD86 through LSD1 inhibition promotes myeloid differentiation and suppresses cell proliferation in human monocytic leukemia cells , 2017, Oncotarget.
[4] A. Brenner,et al. Novel KDM1A inhibitors induce differentiation and apoptosis of glioma stem cells via unfolded protein response pathway , 2017, Oncogene.
[5] Jian Jin,et al. Inhibitors of Protein Methyltransferases and Demethylases , 2017, Chemical reviews.
[6] M. Kawahara,et al. A novel LSD1 inhibitor NCD38 ameliorates MDS-related leukemia with complex karyotype by attenuating leukemia programs via activating super-enhancers , 2017, Leukemia.
[7] R. Hara,et al. A Novel LSD1 Inhibitor T-3775440 Disrupts GFI1B-Containing Complex Leading to Transdifferentiation and Impaired Growth of AML Cells , 2016, Molecular Cancer Therapeutics.
[8] T. Somervaille,et al. LSD1: biologic roles and therapeutic targeting , 2016, Epigenomics.
[9] Thomas V. O'brien,et al. Pharmacological Inhibition of the Histone Lysine Demethylase KDM1A Suppresses the Growth of Multiple Acute Myeloid Leukemia Subtypes. , 2016, Cancer research.
[10] M. Nakao,et al. Lysine‐specific demethylase‐1 contributes to malignant behavior by regulation of invasive activity and metabolic shift in esophageal cancer , 2016, International journal of cancer.
[11] A. Mai,et al. Discovery of a Novel Inhibitor of Histone Lysine-Specific Demethylase 1A (KDM1A/LSD1) as Orally Active Antitumor Agent. , 2016, Journal of medicinal chemistry.
[12] Frederick M. Lang,et al. Preclinical activity of combined HDAC and KDM1A inhibition in glioblastoma. , 2015, Neuro-oncology.
[13] A. Jordan,et al. Reversible Inhibitors of LSD1 as Therapeutic Agents in Acute Myeloid Leukemia: Clinical Significance and Progress to Date , 2015, Medicinal research reviews.
[14] A. Mai,et al. Pure enantiomers of benzoylamino-tranylcypromine: LSD1 inhibition, gene modulation in human leukemia cells and effects on clonogenic potential of murine promyelocytic blasts. , 2015, European journal of medicinal chemistry.
[15] A. Mai,et al. Pyrrole- and indole-containing tranylcypromine derivatives as novel lysine-specific demethylase 1 inhibitors active on cancer cells , 2015 .
[16] A. Mai,et al. Pure Diastereomers of a Tranylcypromine-Based LSD1 Inhibitor: Enzyme Selectivity and In-Cell Studies. , 2015, ACS medicinal chemistry letters.
[17] jin-quan yu,et al. Palladium(II)-catalyzed highly enantioselective C-H arylation of cyclopropylmethylamines. , 2015, Journal of the American Chemical Society.
[18] A. Mai,et al. Synthesis, biological activity and mechanistic insights of 1-substituted cyclopropylamine derivatives: a novel class of irreversible inhibitors of histone demethylase KDM1A. , 2014, European journal of medicinal chemistry.
[19] T. Höller,et al. Lysine-specific demethylase 1 (LSD1) in hematopoietic and lymphoid neoplasms. , 2014, Blood.
[20] Hong Sun,et al. Pluripotent stem cell protein Sox2 confers sensitivity to LSD1 inhibition in cancer cells. , 2013, Cell reports.
[21] Kristian Helin,et al. Chromatin proteins and modifications as drug targets , 2013, Nature.
[22] Crispin J. Miller,et al. The histone demethylase KDM1A sustains the oncogenic potential of MLL-AF9 leukemia stem cells. , 2012, Cancer cell.
[23] Martin Dugas,et al. Inhibition of the LSD1 (KDM1A) demethylase reactivates the all-trans-retinoic acid differentiation pathway in acute myeloid leukemia , 2012, Nature Medicine.
[24] D. Ward,et al. Novel histone demethylase LSD1 inhibitors selectively target cancer cells with pluripotent stem cell properties. , 2011, Cancer research.
[25] A. Mai,et al. Targeting Histone Demethylases: A New Avenue for the Fight against Cancer. , 2011, Genes & cancer.
[26] J. Jansen,et al. Gfi1 and Gfi1b: key regulators of hematopoiesis , 2010, Leukemia.
[27] A. Mai,et al. Biochemical, structural, and biological evaluation of tranylcypromine derivatives as inhibitors of histone demethylases LSD1 and LSD2. , 2010, Journal of the American Chemical Society.
[28] R. Schüle,et al. Lysine-specific demethylase 1 (LSD1) is highly expressed in ER-negative breast cancers and a biomarker predicting aggressive biology. , 2010, Carcinogenesis.
[29] Sung Jin Cho,et al. Selective 5-hydroxytryptamine 2C receptor agonists derived from the lead compound tranylcypromine: identification of drugs with antidepressant-like action. , 2009, Journal of medicinal chemistry.
[30] R. Versteeg,et al. Lysine-specific demethylase 1 is strongly expressed in poorly differentiated neuroblastoma: implications for therapy. , 2009, Cancer research.
[31] F. Forneris,et al. LSD1: oxidative chemistry for multifaceted functions in chromatin regulation. , 2008, Trends in biochemical sciences.
[32] Jonghwan Kim,et al. Epigenetic regulation of hematopoietic differentiation by Gfi-1 and Gfi-1b is mediated by the cofactors CoREST and LSD1. , 2007, Molecular cell.
[33] F. Forneris,et al. Structural Basis of LSD1-CoREST Selectivity in Histone H3 Recognition* , 2007, Journal of Biological Chemistry.
[34] Gratien G. Prefontaine,et al. Opposing LSD1 complexes function in developmental gene activation and repression programmes , 2007, Nature.
[35] T. Jenuwein,et al. Cooperative demethylation by JMJD2C and LSD1 promotes androgen receptor-dependent gene expression , 2007, Nature Cell Biology.
[36] Min Gyu Lee,et al. An essential role for CoREST in nucleosomal histone 3 lysine 4 demethylation , 2005, Nature.
[37] Andrea Mattevi,et al. Insights into the mode of inhibition of human mitochondrial monoamine oxidase B from high-resolution crystal structures , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[38] A. Eschenmoser,et al. Preparation of N‐Aminoaziridines: trans‐1‐Amino‐2,3‐Diphenylaziridine, 1‐Amino‐2‐Phenylaziridine, and 1‐Amino‐2‐Phenylaziridinium Acetate , 2003 .
[39] J B Houston,et al. Utility of in vitro drug metabolism data in predicting in vivo metabolic clearance. , 1994, Biochemical pharmacology.
[40] Shuyan Xu,et al. From Plasma Sources to Nanoassembly WILEY-VCH Verlag GmbH & Co. KGaA , 2013 .